SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2023 on Thursday, January 26, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details:
| /investor-relations/default.aspx |
| Thursday, January 26, 2023 |
| 1:30 p.m. PDT / 4:30 p.m. EDT |
| London, Thursday, January 26, 2023, 9:30 p.m. GMT |
| Sydney, Friday, January 27, 2023, 8:30 a.m. AEDT |
Please note: ResMed does not use outside phone lines to access the earnings call; the call is accessible via the above webcast link only.
A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from January 26, 2023, until February 9, 2023, at:
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
| For investors | For media |
| Amy Wakeham | Jayme Rubenstein |
| +1 858.836.5000 | +1 858.836.6798 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$214.53 |
| Daily Change: | 0.54 0.25 |
| Daily Volume: | 1,447,016 |
| Market Cap: | US$31.490B |
April 03, 2025 January 30, 2025 October 24, 2024 September 30, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
